Central Venous Pressure-Guided Hydration Beneficial in CKD, CHF

Share this content:
Central Venous Pressure-Guided Hydration Beneficial in CKD, CHF
Central Venous Pressure-Guided Hydration Beneficial in CKD, CHF

FRIDAY, Dec. 11, 2015 (HealthDay News) -- For patients with chronic kidney disease (CKD) and congestive heart failure (CHF) undergoing coronary procedures, central venous pressure (CVP)-guided hydration is associated with reduced risk of contrast-induced nephropathy (CIN), according to a study published online Dec. 9 in JACC: Cardiovascular Interventions.

Geng Qian, M.D., from the Chinese People's Liberation Army General Hospital in Peking, and colleagues conducted a prospective comparative trial involving 264 patients with CKD and CHF undergoing coronary procedures. Patients were randomized to CVP-guided hydration or standard hydration (132 patients in each group). The hydration infusion rate was dynamically adjusted according to CVP level every hour in the CVP-guided group.

The researchers found that the total mean volume of isotonic saline administered was significantly higher in the CVP-guided hydration group than the control group (P < 0.001). CIN occurred less often in the CVP-guided hydration group (15.9 versus 29.5 percent in the control group; P = 0.006). There was no difference between the groups in the incidences of acute heart failure during the hydration (3.8 versus 3.0 percent; P = 0.500).

"CVP-guided fluid administration can safely and effectively reduce the risk of CIN in patients with CKD and CHF," the authors write.

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Incident Contrast Sensitivity Common in Middle-Aged Adults

Incident Contrast Sensitivity Common in Middle-Aged Adults

Factors linked to elevated risk include cadmium level in highest quintile, older age, more plaque sites

Tafamidis Treats Transthyretin Amyloid Cardiomyopathy

Tafamidis Treats Transthyretin Amyloid Cardiomyopathy

Reduces all-cause mortality, cardiovascular-related hospitalizations compared with placebo

Scribes Improve Physician Workflow, Patient Interaction

Scribes Improve Physician Workflow, Patient Interaction

Scribes lower EHR documentation burden for doctors and increase time spent interacting with patients

is free, fast, and customized just for you!




Already a member?

Sign In Now »